An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.